

Henry Leonidas Gomez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8454647/publications.pdf>

Version: 2024-02-01

89
papers

13,066
citations

53660

45
h-index

45213

90
g-index

91
all docs

91
docs citations

91
times ranked

16345
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012, 379, 633-640. | 6.3 | 1,165 |
| 2 | Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5538-5546. | 0.8 | 948 |
| 3 | Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4236-4244. | 0.8 | 621 |
| 4 | Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118. | 13.9 | 621 |
| 5 | High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009, 374, 1512-1520. | 6.3 | 588 |
| 6 | A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1873. | 3.8 | 531 |
| 7 | Emergence of Constitutively Active Estrogen Receptor- β Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767. | 3.2 | 529 |
| 8 | A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , 2011, 9, 204. | 1.8 | 500 |
| 9 | Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. <i>Journal of Clinical Oncology</i> , 2007, 25, 5210-5217. | 0.8 | 465 |
| 10 | Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 923-932. | 13.9 | 452 |
| 11 | RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509. | 3.2 | 428 |
| 12 | Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. <i>Cancer Discovery</i> , 2014, 4, 232-245. | 7.7 | 413 |
| 13 | Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5544-5552. | 0.8 | 407 |
| 14 | Planning cancer control in Latin America and the Caribbean. <i>Lancet Oncology, The</i> , 2013, 14, 391-436. | 5.1 | 394 |
| 15 | Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2999-3005. | 0.8 | 321 |
| 16 | Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042. | 0.8 | 315 |
| 17 | BIM Expression in Treatment-Negative Cancers Predicts Responsiveness to Kinase Inhibitors. <i>Cancer Discovery</i> , 2011, 1, 352-365. | 7.7 | 268 |
| 18 | PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. <i>Breast Cancer Research</i> , 2014, 16, 406. | 2.2 | 267 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059. | 15.2 | 219 |
| 20 | First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772. | 0.8 | 190 |
| 21 | Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5351-5361. | 3.2 | 185 |
| 22 | Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. <i>Lancet Oncology</i> , The, 2007, 8, 203-211. | 5.1 | 175 |
| 23 | Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2221-2231. | 0.8 | 148 |
| 24 | The phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 751-759. | 2.7 | 146 |
| 25 | Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. <i>Clinical Cancer Research</i> , 2010, 16, 2688-2695. | 3.2 | 137 |
| 26 | Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1947-1953. | 0.8 | 128 |
| 27 | Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6346-6358. | 0.4 | 124 |
| 28 | Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database. <i>Clinical Breast Cancer</i> , 2010, 10, 294-300. | 1.1 | 119 |
| 29 | Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3703-3713. | 3.2 | 119 |
| 30 | RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227. | 3.4 | 118 |
| 31 | Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 696-706. | 5.1 | 109 |
| 32 | Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657. | 3.2 | 108 |
| 33 | Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 333-343. | 1.1 | 106 |
| 34 | Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. <i>Science Translational Medicine</i> , 2016, 8, 334ra53. | 5.8 | 105 |
| 35 | Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 4899. | 1.6 | 91 |
| 36 | Breast Cancer in Young Women in Latin America: An Unmet, Growing Burden. <i>Oncologist</i> , 2013, 18, 1298-1306. | 1.9 | 84 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Analysis of dermatologic events in patients with cancer treated with lapatinib. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 485-493. | 1.1 | 78 |
| 38 | Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 409-418. | 1.1 | 65 |
| 39 | Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408. | 0.8 | 65 |
| 40 | In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. <i>Scientific Reports</i> , 2017, 7, 1526. | 1.6 | 60 |
| 41 | A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression. <i>Clinical Cancer Research</i> , 2006, 12, 832-838. | 3.2 | 59 |
| 42 | A randomized phase II study of lapatinib+Pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 471-482. | 1.1 | 55 |
| 43 | Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3. <i>Psycho-Oncology</i> , 2014, 23, 173-182. | 1.0 | 55 |
| 44 | Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>Haematologica</i> , 2013, 98, 357-363. | 1.7 | 51 |
| 45 | A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. <i>Npj Genomic Medicine</i> , 2016, 1, 15015. | 1.7 | 50 |
| 46 | PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R27. | 2.2 | 49 |
| 47 | Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. <i>Clinical and Translational Oncology</i> , 2017, 19, 1478-1488. | 1.2 | 46 |
| 48 | Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib. <i>Journal of Clinical Oncology</i> , 2008, 26, 1253-1259. | 0.8 | 44 |
| 49 | A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 755-766. | 1.1 | 42 |
| 50 | Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. <i>World Journal of Clinical Oncology</i> , 2016, 7, 387. | 0.9 | 42 |
| 51 | A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1049-1056. | 1.1 | 39 |
| 52 | Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 3.0 | 37 |
| 53 | Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 335-341. | 0.7 | 36 |
| 54 | A phase 3 trial comparing capecitabine in combination with Sorafenib or placebo for treatment of locally advanced or metastatic HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 228. | 0.7 | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Breast Cancer in Young Women in Latin America: An Unmet, Growing Burden. <i>Oncologist</i> , 2013, 18, 26-34. | 1.9 | 33 |
| 56 | Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. <i>Cancer Research</i> , 2020, 80, 1893-1901. | 0.4 | 29 |
| 57 | Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 20282-20292. | 0.8 | 28 |
| 58 | Advanced Extramammary Paget's Disease of the Groin, Penis, and Scrotum. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S13107. | 0.6 | 27 |
| 59 | Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 507-515. | 1.1 | 27 |
| 60 | Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037. | 3.0 | 24 |
| 61 | Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. <i>World Journal of Clinical Oncology</i> , 2018, 9, 33-41. | 0.9 | 23 |
| 62 | Pazopanib: an antiangiogenic drug in perspective. <i>Future Oncology</i> , 2009, 5, 1335-1348. | 1.1 | 22 |
| 63 | Small-Cell Cancer of the Breast: What Is the Optimal Treatment? A Report and Review of Outcomes. <i>Clinical Breast Cancer</i> , 2012, 12, 287-292. | 1.1 | 22 |
| 64 | Implication of miRNA in the diagnosis and treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1265-1275. | 1.1 | 20 |
| 65 | A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American) Tj ETQq1 1.0.784314ogBT /Ove | 1.0 | 20 |
| 66 | Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1127-1134. | 1.2 | 20 |
| 67 | The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. <i>British Journal of Haematology</i> , 2002, 118, 218-228. | 1.2 | 19 |
| 68 | PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2014, 7, 142-148. | 0.6 | 18 |
| 69 | Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. <i>Biomarkers in Medicine</i> , 2019, 13, 1481-1491. | 0.6 | 16 |
| 70 | Behaviour of breast cancer molecular subtypes through tumour progression. <i>Clinical and Translational Oncology</i> , 2012, 14, 481-485. | 1.2 | 15 |
| 71 | Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 239-246.e4. | 1.1 | 15 |
| 72 | A Phase II Study of Neoadjuvant Gemcitabine Plus Doxorubicin in Stage IIIB Breast Cancer: A Preliminary Report. <i>Seminars in Oncology</i> , 2001, 28, 57-61. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2010, 26, 767-775. | 0.9 | 13 |
| 74 | Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. <i>Journal of Surgical Oncology</i> , 2017, 115, 647-662. | 0.8 | 13 |
| 75 | Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience. <i>PLoS ONE</i> , 2020, 15, e0237811. | 1.1 | 12 |
| 76 | Ifosfamide plus Cisplatin as Primary Chemotherapy of Advanced Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 67, 168-171. | 0.6 | 11 |
| 77 | Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical Trials. <i>Clinical Breast Cancer</i> , 2012, 12, 240-246. | 1.1 | 11 |
| 78 | Combined lapatinib and paclitaxel in HER2-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 308-309. | 12.5 | 10 |
| 79 | Topoisomerase II- α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. <i>Breast</i> , 2011, 20, 39-45. | 0.9 | 9 |
| 80 | Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer. <i>CNS Oncology</i> , 2015, 4, 137-145. | 1.2 | 8 |
| 81 | Breast cancer subtype and survival among Indigenous American women in Peru. <i>PLoS ONE</i> , 2018, 13, e0201287. | 1.1 | 8 |
| 82 | Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. <i>Ecancermedicalscience</i> , 2019, 13, 896. | 0.6 | 8 |
| 83 | Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 346-352. | 0.5 | 7 |
| 84 | Global experience with ixabepilone in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 683-692. | 1.1 | 3 |
| 85 | Role of undifferentiation markers and androgen receptor expression in triple-negative breast cancer. <i>Breast Journal</i> , 2019, 25, 1316-1319. | 0.4 | 3 |
| 86 | Prolonged Disease Control in a Patient With Anthracycline- and Taxane-Resistant Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, E1-E3. | 1.1 | 1 |
| 87 | Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2012, 5, 152-157. | 0.6 | 1 |
| 88 | Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 392-393. | 0.2 | 1 |
| 89 | PIK3CA mutated, hormonal receptors and HER2: individual targets but partnered in the escape to targeted therapy in breast cancer. <i>Translational Cancer Research</i> , 2016, 5, S789-S793. | 0.4 | 0 |